Analysts flock to raise Novo Nordisk share price target following upgrade
Equity analysts are very positive when it comes to the Novo Nordisk stock, especially after the pharmaceutical firm upgraded its guidance in connection with its Q1 report on Friday.
by marketwire, translated by daniel pedersen
Friday morning last week, Novo Nordisk caught the stock market by surprise when the company released its first quarterly report for 2022 half a week before it was scheduled to be published.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk upgrades full-year guidance
For subscribers
Novo Nordisk remains coy over Wegovy blockbuster potential
For subscribers
.jpg&w=384&q=75)
